Angelo Aguilar

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Shaomeng Wang, Wei Sun, Yujun Zhao et al. · Cancer Research · 2014 · 338 citations · Full text

Medicine, Oncology, Pharmacology +8

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Yangbing Li, Jiuling Yang, Angelo Aguilar et al. · Journal of Medicinal Chemistry · 2018 · 299 citations · Full text

Medicine, Oncology, Pharmacology +10

Discovery of 4-((3′<i>R</i>,4′<i>S</i>,5′<i>R</i>)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Angelo Aguilar, Jianfeng Lü, Liu Liu et al. · Journal of Medicinal Chemistry · 2017 · 203 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders

Jiuling Yang, Yangbing Li, Angelo Aguilar et al. · Journal of Medicinal Chemistry · 2019 · 173 citations · Full text

Life Sciences, Molecular Biology, Oncology +7

The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity

Jiajia Zhou, Ilona Kryczek, Shasha Li et al. · Nature Immunology · 2021 · 105 citations · Full text

Life Sciences, Cancer Biology, Immunology +16